scholarly journals Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?

2005 ◽  
Vol 21 (1) ◽  
pp. 104-108 ◽  
Author(s):  
Polat Dursun ◽  
Ezgi Demirtaş ◽  
Ahmet Bayrak ◽  
Hakan Yarali
Keyword(s):  
Risk Factor ◽  
Heart Disease ◽  
Paraoxonase 1 ◽  
Pon1 Activity ◽  
Additional Risk Factor ◽  
Additional Risk ◽  
Serum Paraoxonase

HLA-DP variation as additional risk factor in IDDM

Diabetes ◽  
1990 ◽  
Vol 39 (7) ◽  
pp. 855-857 ◽  
Author(s):  
S. Easteal ◽  
M. R. Kohonen-Corish ◽  
P. Zimmet ◽  
S. W. Serjeantson
Keyword(s):  
Risk Factor ◽  
Additional Risk Factor ◽  
Additional Risk

Prevalence and prognostic impact of left ventricular systolic dysfunction after acute myocardial infarction

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T.J Jernberg ◽  
E.O Omerovic ◽  
E.H Hamilton ◽  
K.L Lindmark ◽  
L.D Desta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Risk Factor ◽  
Reperfusion Therapy ◽  
Left Ventricular ◽  
Funding Source ◽  
Additional Risk Factor ◽  
Additional Risk

Abstract Background Left ventricular dysfunction after an acute myocardial infarction (MI) is associated with poor outcome. The PARADISE-MI trial is examining whether an angiotensin receptor-neprilysin inhibitor reduces the risk of cardiovascular death or worsening heart failure (HF) in this population. The aim of this study was to examine the prevalence and prognosis of different subsets of post-MI patients in a real-world setting. Additionally, the prognostic importance of some common risk factors used as risk enrichment criteria in the PARADISE-MI trial were specifically examined. Methods In a nationwide myocardial infarction registry (SWEDEHEART), including 87 177 patients with type 1 MI between 2011–2018, 3 subsets of patients were identified in the overall MI cohort (where patients with previous HF were excluded); population 1 (n=27 568 (32%)) with signs of acute HF or an ejection fraction (EF) <50%, population 2 (n=13 038 (15%)) with signs of acute HF or an EF <40%, and population 3 (PARADISE-MI like) (n=11 175 (13%)) with signs of acute HF or an EF <40% and at least one risk factor (Age ≥70, eGFR <60, diabetes mellitus, prior MI, atrial fibrillation, EF <30%, Killip III-IV and STEMI without reperfusion therapy). Results When all MIs, population 1 (HF or EF <50%), 2 (HF or EF <40%) and 3 (HF or EF <40% + additional risk factor (PARADISE-MI like)) were compared, the median (IQR) age increased from 70 (61–79) to 77 (70–84). Also, the proportion of diabetes (22% to 33%), STEMI (38% to 50%), atrial fibrillation (10% to 24%) and Killip-class >2 (1% to 7%) increased. After 3 years of follow-up, the cumulative probability of death or readmission because of heart failure in the overall MI population and in population 1 to 3 was 17.4%, 26.9%, 37.6% and 41.8%, respectively. In population 2, all risk factors were independently associated with death or readmission because of HF (Age ≥70 (HR (95% CI): 1.80 (1.66–1.95)), eGFR <60 (1.62 (1.52–1.74)), diabetes mellitus (1.35 (1.26–1.44)), prior MI (1.16 (1.07–1.25)), atrial fibrillation (1.35 (1.26–1.45)), EF <30% (1.69 (1.58–1.81)), Killip III-IV (1.34 (1.19–1.51)) and STEMI without reperfusion therapy (1.34 (1.21–1.48))) in a multivariable Cox regression analysis. The risk increased with increasing number of risk factors (Figure 1). Conclusion Depending on definition, post MI HF is present in 13–32% of all MI patients and is associated with a high risk of subsequent death or readmission because of HF. The risk increases significantly with every additional risk factor. There is a need to optimize management and improve outcomes for this high risk population. Figure 1 Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Novartis

scholarly journals A critical review on human serum Paraoxonase-1 in the literature: truths and misconceptions

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Michael Mackness ◽  
Eser Yildirim Sozmen
Keyword(s):  
Heart Disease ◽  
Experimental Design ◽  
Human Serum ◽  
Critical Review ◽  
Neurological Diseases ◽  
Rapid Expansion ◽  
Paraoxonase 1 ◽  
Serum Paraoxonase ◽  
Inflammatory Component ◽  
Biomedical Fields

AbstractHuman serum paraoxonase 1 (PON1) appears to play an important role in the development of a large variety of diseases with an inflammatory component including heart disease, diabetes, rheumatic diseases, neurological diseases and cancer. As such PON1 research is rapidly expanding into new biomedical fields. Unfortunately, this rapid expansion has resulted in a number of problems due to poor experimental design and the spreading of misconceptions in the literature. This review seeks to describe the basic properties of PON1 and the problems and misconceptions that have arisen.

scholarly journals Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

2013 ◽  
pp. 1545 ◽  
Author(s):  
Yakup Albayrak ◽  
Cüneyt Ünsal ◽  
Neslihan Albayrak ◽  
Murat Kuloglu ◽  
Kenji Hashimoto
Keyword(s):  
Paraoxonase 1 ◽  
Pon1 Activity ◽  
Serum Paraoxonase

scholarly journals Socio-economic impact in the late diagnosis of retinopathy of prematurity

2016 ◽  
Vol 11 (1) ◽  
pp. 45-48
Author(s):  
Daniela POPESCU ◽  
◽  
Dumitru MATEI ◽  
◽  
◽  
...  
Keyword(s):  
Risk Factor ◽  
Human Resources ◽  
Retinopathy Of Prematurity ◽  
Social Impact ◽  
Treatment Programs ◽  
Additional Risk Factor ◽  
Fundus Examination ◽  
Additional Risk ◽  
Simple Process ◽  
Socio Economic Impact

Retinopathy of prematurity (ROP) represents a determinate cause of blindness in children that could be avoided. Blindness due to ROP and the stage of it when its being diagnosed is mostly determined by: socioeconomic degree of country development; availability of the screening in neonatal care; gestational age and hospital screenings; treatment programs available at any given time in the country; screening and treatment costs (material and human resources). ROP is the number one cause of blindness in Romania at the time being. Early discovery decreases exponentially the chances of blindness onset. Low birth weight (LBW), fewer than 1,500 g, represents an additional risk factor together with the degree of prematurity. Mandatory screening both during hospitalization as well as in the first 4-6 weeks after birth may avoid a major social problem. It is a simple process – eye exam with fundus examination – and it depends entirely on the availability, consistency and seriouseness of the parents. Thus a major social impact with disastrous consequences could be avoided.

scholarly journals L’importanza del vaccino anti Covid-19 nei pazienti affetti da malattia del rene policistico autosomico dominante dell’adulto (ADPKD)

2021 ◽  
Vol 33 ◽  
pp. 84-87
Author(s):  
Maria Teresa Sciarrone Alibrandi ◽  
Giancarlo Joli ◽  
Rodolfo F. Rivera ◽  
Elena Brioni ◽  
Romina Bucci ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Risk Factor ◽  
Kidney Disease ◽  
Kidney Injury ◽  
Point Of View ◽  
Additional Risk Factor ◽  
Additional Risk ◽  
The Moment ◽  
Clear Relation ◽  
Related Mortality

The SARS-CoV-2 (Covid-19) infection affected about 106 million people worldwide and the total amount of casualties now sits at a staggering 2 millions. Chronic Kidney Disease (CKD) emerged as the first risk factor in worst patients, not considering old age. Kidney disease and acute kidney injury have been correlated with a higher chance of death. This combination of CKD and higher Covid-19 related mortality requires immediate response from a prevention point of view at first and then from a therapeutic one. There is not a clear relation between Covid-19 and ADPKD. What can be inferred is the following: Covid uses the ACE2 receptors on cell membranes to “lock on” its target. It is well-established in fact that the RAAS is more active in ADPKD patients and it may represent an additional risk factor for these patients. At the moment three Covid-19 vaccines have been approved, and two of them have been already administered, such as Pfizer BioNTech and Moderna, sharing the same mechanism. AstraZeneca released a third option. All of them are completely safe and reliable, each one with its own feature. Therefore, considering how delicate ADPKD patients are, vaccination is strongly recommended.

Sign in / Sign up

Export Citation Format

Share Document